Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase II Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BNC210 in Hospitalised Elderly Patients With Agitation

Trial Profile

A Phase II Randomised, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of BNC210 in Hospitalised Elderly Patients With Agitation

Recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Oct 2018

At a glance

  • Drugs BNC 210 (Primary)
  • Indications Agitation
  • Focus Therapeutic Use
  • Sponsors Bionomics
  • Most Recent Events

    • 02 Oct 2018 According to a Bionomics media release, data readout is expected Q1, 2019.
    • 02 Jun 2018 New trial record
    • 24 May 2018 According to a Bionomics media release, this trial has commenced and the first participant has been recruited into the trial.Results of this clinical trial will be available in first quarter of calender year 2019 (Q1, CY2019).
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top